Asher Biotherapeutics has entered into a service agreement with ProBioGen, covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale.
ProBioGen will now advance the development of Asher's lead candidate in immuno-oncology, applying its transposase technology DirectedLuck, which is designed to accelerate time-to-clinic.
Asher Biotherapeutics, a biotech company located in the San Francisco Bay Area, is developing cis-targeted immunotherapies for the potential treatment of cancer, autoimmune and infectious diseases. Andy Yeung, CTO at Asher Biotherapeutics said: "With cell line development and manufacturing laying the foundation for a successful clinical program, working with an experienced and reliable CDMO partner to navigate the challenges associated with it is of utmost importance. With its long-standing expertise and cutting edge technologies we are convinced to have found the right partner in ProBioGen."
Dr René Brecht, ProBioGen's COO added: "We are very excited to work with Asher Biotherapeutics on their lead immunotherapy program. ProBioGen has ample experience with biotherapeutic development and we are proud to support Asher in the advancement of their clinical pipeline."
